Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).

Lung cancer (Amsterdam, Netherlands) - 1 May 2010

Jatoi Aminah, Ritter Howard L, Dueck Amylou, Nguyen Phuong L, Nikcevich Daniel A, Luyun Ronnie F, Mattar Bassam I, Loprinzi Charles L

Abstract excerpt

PURPOSE: This study tested whether infliximab, a chimeric IgG1kappa monoclonal antibody that blocks tumor necrosis factor (TNF) alpha, improves/stabilizes weight loss in elderly and/or poor performance status patients with metastatic non-small cell lung cancer (NSCLC). METHODS: This double-blind trial randomly assigned patients to infliximab/docetaxel (n=32) versus placebo/docetaxel (n=29). The primary endpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Docetaxel

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Fatigue

Share to Infliximab

Share to Quality of Life

Share to Taxoids

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 19665818
DOI: 10.1016/j.lungcan.2009.06.020
PMCID: PMC5951722

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).PMID 19665818Read ↗

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.Semantic proximity Read ↗

Weight change and Impact on prognosis in patients with Advanced Non-small Cell Lung Cancer with Concomitant diabetes mellitus treated with SGLT2 inhibitorsSemantic proximity Read ↗

The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer.Semantic proximity Read ↗

Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.Semantic proximity Read ↗

Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma.Semantic proximity Read ↗

Effectiveness and Durable Outcomes with Second-Line Immunotherapy in Advanced NSCLC in Real World Practice in IndiaSemantic proximity Read ↗

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.Semantic proximity Read ↗

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.